Targeted metabolomic analyses of cellular models of pelizaeus-merzbacher disease reveal plasmalogen and myo-inositol solute carrier dysfunction

Lipids in Health and Disease

Dayan B Goodenowe¹  Lindsay Pelzer¹  Tara Smith¹  Paul L Wood¹ 

[1] Phenomenome Discoveries Inc, 204-407 Downey Road, Saskatoon, SK S7N 4L8, Canada

关键词: peroxisomal disorders;    myo-inositol transporter;    plasmalogens;    158JP oligodendrocytes;    lymphocytes;    fibroblasts;    Pelizaeus-Merzbacher disease;    leukodystrophy;   

Others  :  1212612
DOI  :  10.1186/1476-511X-10-102

 received in 2011-05-16, accepted in 2011-06-17,  发布年份 2011

【 摘 要 】

Background

Leukodystrophies are devastating diseases characterized by dys- and hypo-myelination. While there are a number of histological and imaging studies of these disorders, there are limited biochemical data available. We undertook targeted lipidomic analyses of Pelizaeus-Merzbacher disease (PMD) fibroblasts, PMD lymphocytes, and 158JP oligodendrocytes, a murine model of PMD, to define the lipid changes in these cell models. Further targeted metabolomics analyses were conducted to obtain a preliminary evaluation of the metabolic consequences of lipid changes and gene mutations in these cell models.

Results

In both PMD fibroblasts and lymphocytes, and 158JP oligodendrocytes, ethanolamine plasmalogens were significantly decreased. Labeling studies with 158JP oligodendrocytes further demonstrated a decreased rate of lipid remodeling at sn-2. Targeted metabolomics analyses of these cells revealed dramatic increases in cellular levels of myo-inositol. Further uptake studies demonstrated increased rates of myo-inositol uptake by PMD lymphocytes.

Conclusions

Our data demonstrating PlsEtn decrements, support previous studies indicating leukodystrophy cells possess significant peroxisomal deficits. Our data for the first time also demonstrate that decrements in peroxisomal function coupled with the PLP1 gene defects of PMD, result in changes in the function of membrane myo-inositol solute carriers resulting in dramatic increases in cellular myo-inositol levels.

【 授权许可】

   
2011 Wood et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Costello DJ, Eichler AF, Eichler FS: Leukodystrophies: classification, diagnosis, and treatment. Neurologist 2009, 15:319-28.
• [2]Kohler W: Leulodystrophies with late disease onset: an update. Current Opinions in Neurol 2010, 23:234-241.
• [3]Bonkowsky JL, Nelson C, Kingston JL, Filloux FM, Mundorff MB, Srivastava R: The burden of inherited leukodystrophies in children. Neurology 2010, 75:718-25.
• [4]Singh I, Singh AK, Contreras MA: Peroxisomal dysfunction in inflammatory childhood white matter disorders: an unexpected contributor to neuropathology. J Child Neurol 2009, 24:1147-57.
• [5]Regis S, Grossi S, Corsolini F, Biancheri R, Filocamo M: PLP1 gene duplication causes overexpression and alteration of the PLP/DM20 splicing balance in fibroblasts from Pelizaeus-Merzbacher disease patients. Biochim Biophys Acta 2009, 1792:548-54.
• [6]Baarine M, Ragot K, Genin EC, El Hajj H, Trompier D, Andreoletti P, Ghandour MS, Menetrier F, Cherkaoui-Malki M, Savary S, Lizard G: Peroxisomal and mitochondrial status of two murine oligodendrocytic cell lines (158N, 158JP): potential models for the study of peroxisomal disorders associated with dysmyelination processes. J Neurochem 2009, 111:119-31.
• [7]Willmroth F, Drieling T, Lamla U, Marcushen M, Wark HJ and van Calker D: Sodium-myo-inositol co-transporter (SMIT-1) mRNA is increased in neutrophils of patients with bipolar I disorder and down-regulated under treatment with mood stabilizers. International Journal of Neuropsychopharmacology 2007, 10:63-71.
• [8]Lin X, Ma L, Fitzgerald RL, Ostlund RE Jr: Human sodium/inositol cotransporter 2 (SMIT2) transports inositols but not glucose in L6 cells. Archives of Biochemistry and Biophysics 2009, 481:197-201.
• [9]Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW, Heath D, Yamazaki Y, Flax J, Krenitsky KF, Sparks DL, Lerner A, Friedland RP, Kudo T, Kamino K, Morihara T, Takeda M, Wood PL: Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J Lipid Res 2007, 48:2485-98.
• [10]Wood PL, Khan MA, Moskal JR: Neurochemical analysis of amino acids, polyamines and carboxylic acids: GC-MS quantitation of tBDMS derivatives using ammonia positive chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci 2006, 831:313-9.
• [11]Koizume S, Takizawa S, Fujita K, Aida N, Yamashita S, Miyagi Y, Osaka H: Aberrant trafficking of a proteolipid protein in a mild Pelizaeus-Merzbacher disease. Neuroscience 2006, 141:1861-9.
• [12]Simons M, Kramer EM, Macchi P, Rathke-Hartlieb S, Trotter J, Nave KA, Schulz JB: verexpression of the myelin proteolipid protein leads to accumulation of cholesterol and proteolipid protein in endosomes/lysosomes: implications for Pelizaeus-Merzbacher disease. J Cell Biol 2002, 157:327-36.
• [13]Brites P, Waterham HR, Wanders RJ: Functions and biosynthesis of plasmalogens in health and disease. Biochim Biophys Acta 2004, 1636:219-31.
• [14]Thoms S, Grønborg S, Gärtner J: Organelle interplay in peroxisomal disorders. Trends Mol Med 2009, 15:293-302.
• [15]Hanefeld FA, Brockmann K, Pouwels PJ, Wilken B, Frahm J, Dechent P: Quantitative proton MRS of Pelizaeus-Merzbacher disease: evidence of dys- and hypomyelination. Neurology 2005, 65:701-6.
• [16]Sima AA, Pierson CR, Woltjer RL, Hobson GM, Golden JA, Kupsky WJ, Schauer GM, Bird TD, Skoff RP, Garbern JY: Neuronal loss in Pelizaeus-Merzbacher disease differs in various mutations of the proteolipid protein 1. Acta Neuropathol 2009, 118:531-9.
• [17]Mandel H, Sharf R, Berant M, Wanders RJ, Vreken P, Aviram M: Plasmalogen phospholipids are involved in HDL-mediated cholesterol efflux: insights from investigations with plasmalogen-deficient cells. Biochem Biophys Res Commun 1998, 250:369-73.
• [18]Mankidy R, Ahiahonu PW, Ma H, Jayasinghe D, Ritchie SA, Khan MA, Su-Myat KK, Wood PL, Goodenowe DB: Membrane plasmalogen composition and cellular cholesterol regulation: a structure activity study. Lipids Health Dis 2010, 9:62. BioMed Central Full Text
• [19]Munn NJ, Arnio E, Liu D, Zoeller RA, Liscum L: Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. J Lipid Res 2003, 44:182-92.
• [20]Krämer-Albers EM, Gehrig-Burger K, Thiele C, Trotter J, Nave KA: Perturbed interactions of mutant proteolipid protein/DM20 with cholesterol and lipid rafts in oligodendroglia: implications for dysmyelination in spastic paraplegia. J Neurosci 2006, 26:11743-52.
• [21]Bourgeois F, Coady MJ, Lapointe JY: Determination of transport stoichiometry for two cation-coupled myo-inositol cotransporters: SMIT2 and HMIT. J Physiol 2005, 563:333-43.
• [22]Coady MJ, Wallendorff B, Gagnon DG, Lapointe JY: Identification of a novel Na+/myo-inositol cotransporter. J Biol Chem 2002, 277:35219-24.
• [23]Brockmann K, Dechent P, Wilken B, Rusch O, Frahm J, Hanefeld F: Proton MRS profile of cerebral metabolic abnormalities in Krabbe disease. Neurology 2003, 60:819-25.
• [24]Brockmann K, Dechent P, Meins M, Haupt M, Sperner J, Stephani U, Frahm J, Hanefeld F: Cerebral proton magnetic resonance spectroscopy in infantile Alexander disease. J Neurol 2003, 250:300-6.
• [25]Kruse B, Hanefeld F, Christen HJ, Bruhn H, Michaelis T, Hänicke W, Frahm J: Alterations of brain metabolites in metachromatic leukodystrophy as detected by localized proton magnetic resonance spectroscopy in vivo. J Neurol 1993, 241:68-74.
• [26]Ratai E, Kok T, Wiggins C, Wiggins G, Grant E, Gagoski B, O'Neill G, Adalsteinsson E, Eichler F: Seven-Tesla proton magnetic resonance spectroscopic imaging in adult X-linked adrenoleukodystrophy. Arch Neurol 2008, 65:1488-94.
• [27]Pouwels PJ, Kruse B, Korenke GC, Mao X, Hanefeld FA, Frahm J: Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy. Neuropediatrics 1998, 29:254-64.
• [28]Clements RS Jr: The polyol pathway. A historical review. Drugs 1986, 32(Suppl 2):3-5.
• [29]Bissonnette P, Lahjouji K, Coady MJ, Lapointe JY: Effects of hyperosmolarity on the Na+ -myo-inositol cotransporter SMIT2 stably transfected in the Madin-Darby canine kidney cell line. Am J Physiol Cell Physiol 2008, 295:C791-9.
• [30]Rosenbluth J, Schiff R, Lam P: Effects of osmolality on PLP-null myelin structure: implications re axon damage. Brain Res 2009, 1253:191-7.